Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment.

Borra A, Morbelli S, Zwarthoed C, Bianchi A, Bergesio F, Chauvie S, Zaucha JM, Taszner M, Malkowski B, Biggi A, Thyss A, Darcourt J, Gallamini A.

Am J Nucl Med Mol Imaging. 2019 Jun 15;9(3):176-184. eCollection 2019.

2.

The role of PET/CT in the modern treatment of Hodgkin lymphoma.

Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A.

Cancer Treat Rev. 2019 Jul;77:44-56. doi: 10.1016/j.ctrv.2019.06.002. Epub 2019 Jun 19. Review.

PMID:
31260900
3.

In Search of Platinum Meter Bar for Measurement of Metabolic Tumor Volume in Lymphoma.

Gallamini A.

J Nucl Med. 2019 Aug;60(8):1094-1095. doi: 10.2967/jnumed.119.229252. Epub 2019 Jun 6. No abstract available.

PMID:
31171597
4.

Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing.

Piccaluga PP, Rapezzi D, Gazzola A, Malagola M, Visani G, Gallamini A.

Bone Marrow Transplant. 2019 Jan;54(1):159-163. doi: 10.1038/s41409-018-0268-4. Epub 2018 Aug 16. No abstract available.

PMID:
30116015
5.

Hodgkin lymphoma staging 50 years later: no more knives or needles!

Gallamini A.

Ann Oncol. 2018 Sep 1;29(9):1892-1893. doi: 10.1093/annonc/mdy262. No abstract available.

PMID:
30052746
6.

Reply to H.J.A. Adams et al and C. Mesguich et al.

Gallamini A, Viviani S, Pavoni C, Rambaldi A.

J Clin Oncol. 2018 Jul 10;36(20):2125-2126. doi: 10.1200/JCO.2018.78.7762. Epub 2018 May 23. No abstract available.

PMID:
29791290
7.

Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

Cottereau AS, Buvat I, Kanoun S, Versari A, Casasnovas O, Chauvie S, Clerc J, Gallamini A, Meignan M.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1463-1464. doi: 10.1007/s00259-018-4005-4. Epub 2018 Apr 12. No abstract available.

PMID:
29651546
8.

Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.

Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A.

Leuk Lymphoma. 2018 Nov;59(11):2546-2556. doi: 10.1080/10428194.2018.1434881. Epub 2018 Feb 12.

PMID:
29431555
9.

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A.

J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543. Epub 2018 Jan 23.

PMID:
29360414
10.

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21.

PMID:
29270787
11.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group.

N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: N Engl J Med. 2018 Mar 1;378(9):878.

12.

Interim FDG-PET Imaging in Lymphoma.

Gallamini A, Zwarthoed C.

Semin Nucl Med. 2018 Jan;48(1):17-27. doi: 10.1053/j.semnuclmed.2017.09.002. Epub 2017 Oct 14. Review.

PMID:
29195613
13.

Relapsed/refractory HL: FDG-PET is the trump card.

Gallamini A.

Blood. 2017 Nov 16;130(20):2154-2155. doi: 10.1182/blood-2017-09-806299. No abstract available.

PMID:
29146817
14.

A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility.

Bauckneht M, Morbelli S, Fiz F, Ferrarazzo G, Piva R, Nieri A, Sarocchi M, Spallarossa P, Canepari ME, Arboscello E, Bellodi A, Massaia M, Gallamini A, Bruzzi P, Marini C, Sambuceti G.

Diagnostics (Basel). 2017 Oct 26;7(4). pii: E57. doi: 10.3390/diagnostics7040057.

15.

PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.

Gallamini A, Meignan M.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):1-3. doi: 10.1007/s00259-017-3841-y. Epub 2017 Oct 12. No abstract available.

PMID:
29026947
16.

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.

Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W, Fijolek-Warszewska A, Biggi A, Fallanca F, Kobylecka M, Dziuk M, Woszczyk D, Rybka J, Kroll-Balcerzak R, Bergesio F, Romanowicz A, Chamier-Cieminska A, Kurczab P, Giza A, Lesniewski-Kmak K, Zaucha R, Swietlik D, Wróbel T, Knopinska-Posluszny W, Walewski J, Gallamini A.

Ann Oncol. 2017 Dec 1;28(12):3051-3057. doi: 10.1093/annonc/mdx524.

PMID:
28950332
17.

Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma.

Biggi A, Bergesio F, Chauvie S, Bianchi A, Menga M, Fallanca F, Hutchings M, Gregianin M, Meignan M, Gallamini A.

Q J Nucl Med Mol Imaging. 2017 Jul 27. doi: 10.23736/S1824-4785.17.02993-4. [Epub ahead of print]

PMID:
28750493
18.

Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation.

Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, Ghidella A, Pomposelli E, Miglino M, Ameri P, Emionite L, Ticconi F, Arboscello E, Buschiazzo A, Massimelli EA, Fiordoro S, Borra A, Cossu V, Bozzano A, Ibatici A, Ponzoni M, Spallarossa P, Gallamini A, Bruzzi P, Sambuceti G, Marini C.

J Nucl Med. 2017 Oct;58(10):1638-1645. doi: 10.2967/jnumed.117.191122. Epub 2017 Jun 23.

19.

FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management.

Gallamini A, Borra A.

Mediterr J Hematol Infect Dis. 2017 Apr 15;9(1):e2017029. doi: 10.4084/MJHID.2017.029. eCollection 2017. Review.

20.

Report of the 6th International Workshop on PET in lymphoma.

Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, Kim WS, Trotman J, Barrington S, Duhrsen U, Vander Borght T, Zamagni E, Kraeber-Bodéré F, Messiou C, Rahmouni A, Buvat I, Andre M, Hertzberg M, Oyen W, Casasnovas O, Luminari S, Garderet L, Montravers F, Kobe C, Kluge R, Versari A, Zucca E, Moreau P, Cheson B, Haioun C, Gallamini A, Meignan M.

Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.

PMID:
28264597
21.

Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.

Gallamini A, Kostakoglu L.

J Nucl Med. 2017 Feb;58(2):196-197. doi: 10.2967/jnumed.116.184663. Epub 2016 Nov 10. No abstract available.

22.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A.

J Nucl Med. 2017 Aug;58(8):1249-1254. doi: 10.2967/jnumed.116.184218. Epub 2017 Jan 26.

23.

Response Assessment Criteria and Their Applications in Lymphoma: Part 2.

Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, Nadel H, Kostakoglu L.

J Nucl Med. 2017 Jan;58(1):13-22. doi: 10.2967/jnumed.116.184242. Epub 2016 Nov 22. Review.

24.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
25.

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.

Romano A, Parrinello NL, Vetro C, Tibullo D, Giallongo C, La Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, Di Raimondo F.

Oncotarget. 2016 Oct 11;7(41):67333-67346. doi: 10.18632/oncotarget.12024.

26.

Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.

Tardy MP, Gastaud L, Boscagli A, Peyrade F, Gallamini A, Thyss A.

Hematol Oncol. 2017 Dec;35(4):875-877. doi: 10.1002/hon.2338. Epub 2016 Aug 19.

PMID:
27539158
27.

Clinical presentation and staging of Hodgkin lymphoma.

Gallamini A, Hutchings M, Ramadan S.

Semin Hematol. 2016 Jul;53(3):148-54. doi: 10.1053/j.seminhematol.2016.05.005. Epub 2016 May 13. Review.

PMID:
27496305
28.

The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).

Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A.

Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28.

PMID:
27133138
29.

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.

La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G.

J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4.

30.

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16.

PMID:
26475305
31.

Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014.

Meignan M, Gallamini A, Haioun C, Barrington S, Itti E, Luminari S, Polliack A.

Leuk Lymphoma. 2015 May;56(5):1229-32. doi: 10.3109/10428194.2015.1029748.

PMID:
26086968
32.

Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?

Gallamini A, Kostakoglu L.

Ann Oncol. 2015 Jun;26(6):1045-7. doi: 10.1093/annonc/mdv160. No abstract available.

PMID:
26003616
33.

Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.

Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A.

Haematologica. 2015 Jun;100(6):786-93. doi: 10.3324/haematol.2014.123273. Epub 2015 Mar 6.

34.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

35.

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R.

Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.

PMID:
25650091
36.

FDG PET/CT imaging as a biomarker in lymphoma.

Meignan M, Itti E, Gallamini A, Younes A.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33. doi: 10.1007/s00259-014-2973-6. Epub 2015 Jan 9. Review.

PMID:
25573631
37.

Positron Emission Tomography (PET) in Oncology.

Gallamini A, Zwarthoed C, Borra A.

Cancers (Basel). 2014 Sep 29;6(4):1821-89. doi: 10.3390/cancers6041821. Review.

38.

Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.

Chiaravalloti A, Danieli R, Caracciolo CR, Travascio L, Cantonetti M, Gallamini A, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O.

Medicine (Baltimore). 2014 Aug;93(8):e50. doi: 10.1097/MD.0000000000000050.

39.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M.

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27. No abstract available.

40.

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.

Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, Gallamini A, Siegel BA, Cashen AF, Véra P, Tilly H, Versari A, Itti E.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22. doi: 10.1007/s00259-014-2822-7. Epub 2014 Jun 6.

PMID:
24902639
41.

SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.

Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, Pimpinelli N, Rossi G, Zinzani PL, Tura S.

Ann Oncol. 2014 Dec;25(12):2339-50. doi: 10.1093/annonc/mdu152. Epub 2014 Apr 9.

42.

WIDEN: A tool for medical image management in multicenter clinical trials.

Chauvie S, Biggi A, Stancu A, Cerello P, Cavallo A, Fallanca F, Ficola U, Gregianin M, Guerra UP, Chiaravalloti A, Schillaci O, Gallamini A.

Clin Trials. 2014 Jun;11(3):355-361. doi: 10.1177/1740774514525690.

PMID:
24711610
43.

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.

Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, Olivieri A, Benedetti F, Todeschini G, Rossi G, Salvi F, Bruno B, Baldini L, Ferreri A, Patti C, Tarella C, Pileri S, Dodero A.

Leukemia. 2014 Sep;28(9):1885-91. doi: 10.1038/leu.2014.79. Epub 2014 Feb 20.

44.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

45.

Role of PET in lymphoma.

Gallamini A, Borra A.

Curr Treat Options Oncol. 2014 Jun;15(2):248-61. doi: 10.1007/s11864-014-0278-4. Review.

PMID:
24619427
46.

Interim and end-treatment positron emission tomography scan in aggressive B-cell lymphoma: we still lack an interpretation key.

Gallamini A, Polliack A.

Leuk Lymphoma. 2014 Jul;55(7):1447-8. doi: 10.3109/10428194.2014.881482. Epub 2014 Mar 18. No abstract available.

PMID:
24588737
47.

Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.

Sorasio R, Bonferroni M, Grasso M, Strola G, Rapezzi D, Marenchino D, Di Marco C, Castellino C, Mattei D, Mordini N, Fiore F, Celeghini I, Borra A, Ghiglia A, Gallamini A.

Biol Blood Marrow Transplant. 2014 May;20(5):717-23. doi: 10.1016/j.bbmt.2014.02.002. Epub 2014 Feb 11.

48.

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Franceschetto A, Boccomini C, Franceschetti S, Salvi F, Raimondo FD, Carella AM, Micol Q, Balzarotti M, Musto P, Federico M.

Ann Oncol. 2014 Feb;25(2):442-7. doi: 10.1093/annonc/mdt562. Epub 2014 Jan 10.

PMID:
24412823
49.

Standard therapies versus novel therapies in Hodgkin lymphoma.

Gallamini A, Di Raimondo F, La Nasa G, Romano A, Borra A, Greco M.

Immunol Lett. 2013 Sep-Oct;155(1-2):56-9. doi: 10.1016/j.imlet.2013.09.011. Epub 2013 Oct 16. Review.

PMID:
24140162
50.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi.

Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1.

Supplemental Content

Loading ...
Support Center